GS-9131 + BIC + TAF + ARV regimen + DRV + RTV
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Apr 3, 2018 → Dec 9, 2019
NCT ID
NCT03472326About GS-9131 + BIC + TAF + ARV regimen + DRV + RTV
GS-9131 + BIC + TAF + ARV regimen + DRV + RTV is a phase 2 stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03472326. Target conditions include HIV-1-infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03472326 | Phase 2 | Terminated |
Competing Products
20 competing products in HIV-1-infection